{
    "title": "Steroidal Medicament for the Treatment of Diabetes",
    "inventor_name": "Louis Obyo Obyo Nelson",
    "publication_year": 2003,
    "device_name": "Antidiabetic Phaytopharmaceutical",
    "goal": "To cure or induce remission of diabetes mellitus by oral administration of a plant-derived steroidal compound.",
    "problem_addressed": "Diabetes mellitus (hyperglycemia) requiring lifelong insulin injections and diet management.",
    "concept_summary": "Compounds isolated from the leaves of Vernonia amygdalina are formulated into an oral pharmaceutical composition. The steroidal molecules are claimed to enhance insulin sensitivity, promote beta-cell regeneration, and thereby cure diabetes without toxicity.",
    "detailed_description": "The invention (US Patent 6,531,461 / GB 2,378,652) discloses a class of steroidal compounds (general structure A) and their metal salts, isolated from Vernonia amygdalina leaves. The leaves are dried, ground, and extracted with a 1:1 water-ethanol mixture in a Soxhlet extractor. The crude extract is filtered and concentrated, then purified by chromatography to yield the active compounds. The compounds are administered orally (e.g., 100 mg three times daily) in capsule, tablet, or syrup form. Pre-clinical trials in hyperglycemic mammals showed restoration of insulin activity within six months; a human trial with 26 patients receiving the extract for six months reported remission of diabetes after three months and no required diet discipline. The composition may contain sodium, potassium, or lithium salts and carriers such as glucose syrup, starch, or CMC.",
    "category": "Medical & Dental Technologies",
    "principles": [
        "Herbal extraction",
        "Steroidal chemistry",
        "Insulin sensitisation",
        "Beta-cell regeneration"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Medicinal Chemistry",
        "Botany"
    ],
    "mechanisms_of_action": [
        "Enhance insulin sensitivity",
        "Promote regeneration of pancreatic beta-cells",
        "Reduce blood glucose levels"
    ],
    "materials": [
        "Vernonia amygdalina leaf",
        "Ethanol",
        "Water",
        "Sodium salt",
        "Potassium salt",
        "Lithium salt",
        "Glucose syrup",
        "Starch",
        "Carboxymethylcellulose (CMC)",
        "Alcohol solution"
    ],
    "energy_sources": [],
    "inputs": [
        "Plant leaves",
        "Solvent (water-ethanol)",
        "Patients with diabetes"
    ],
    "outputs": [
        "Oral dosage form (capsule, tablet, syrup)",
        "Reduced blood glucose",
        "Remission of diabetes"
    ],
    "claimed_performance": "Cure of diabetes mellitus; remission observed after three months of oral dosing; no known toxicity; restoration of full insulin activity within six months.",
    "experimental_evidence": "A clinical trial with 26 hyperglycemic patients receiving 100 mg of the extract three times daily for six months showed that after the first month diet discipline was no longer required and after three months disease remission was observed. All volunteers were reported to have recovered and returned to normal life.",
    "replication_status": "Clinical trial performed; no independent replication reported in the article.",
    "keywords": [
        "diabetes",
        "Vernonia amygdalina",
        "herbal medicine",
        "steroidal compound",
        "oral antidiabetic",
        "beta-cell regeneration"
    ],
    "related_technologies": [
        "Insulin therapy",
        "Thiazolidine derivatives",
        "Rosiglitazone",
        "Oral antidiabetic agents"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.8,
    "practicability_score": 0.7,
    "fringe_score": 0.4,
    "evidence_strength": 0.5,
    "risk_score": 0.2,
    "trl_estimate": 5,
    "source_urls": [
        "http://v3.espacenet.com/publicationDetails/biblio?adjacent=true&KC=A&date=20030219&NR=2378652A&DB=EPODOC&locale=en_EP&CC=GB&FT=D",
        "http://www.ngrguardiannews.com/editorial_opinion/article02/indexn2_html?pdate=150209&ptitle=Two%20Nigerian%20Heroes"
    ],
    "organizations": [
        "GDPAU (New Jersey pharmaceutical company)",
        "United States Patent Office",
        "Federal Ministry of Health (Nigeria)",
        "Nigeria Institute for Pharmaceutical Research"
    ],
    "applications": [
        "Treatment of type I and type II diabetes",
        "Oral antidiabetic medication",
        "Therapeutic regeneration of pancreatic beta-cells"
    ],
    "limitations": [
        "Small patient sample size (31 subjects total)",
        "No peer-reviewed publication of trial data",
        "Potential variability in plant compound concentration",
        "Lack of long-term safety data"
    ],
    "open_questions": [
        "Exact biochemical pathway of beta-cell regeneration",
        "Standardisation of extraction and dosage",
        "Efficacy across diverse diabetic populations",
        "Long-term side-effects and toxicity",
        "Scalability of production from plant material"
    ],
    "red_flags": [
        "Extraordinary claim of curing diabetes without insulin",
        "Absence of independent replication or peer-reviewed evidence",
        "Potential for unverified efficacy leading to false hope"
    ],
    "evidence_quotes": [
        "Clinical trials have shown that the drug indeed cures diabetes.",
        "The 26 patients receiving the initial extract no longer required to maintain diet discipline after the first month and examination showed remission of the disease after 3 months.",
        "All volunteers now appear to have recovered from the disease and have returned to their normal life prior to the diagnosis of the disease.",
        "The compounds exhibit no known toxicity when administered to either hyperglycemic or non-hyperglycemic mammals.",
        "The compounds may bring about cell regeneration as trials involving hyperglycemic mammals have resulted in the restoration of complete insulin activity within six months."
    ]
}